Amina Chentouf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amina Chentouf has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Wefa Boughrara
Ecole Supérieure en Sciences Biologiques d’Oran (ESSBO), Oran, Algeria
4 shared publications Mohand Laid Oubaiche
Service de neurologie, C.H. et universitaire d’Oran, Oran, Algérie
3 shared publications- Amel Alioua Berrebbah
Laboratoire de Toxicologie, Environnement et santé, LATES, USTO-MB, Oran, Université des Sciences et Technologie Oran-Mohamed Boudiaf USTO-MB, Oran, Algeria
2 shared publications - Fatma Belhoucine
Laboratoire de Toxicologie, Environnement et santé, LATES, USTO-MB, Oran, Université des Sciences et Technologie Oran-Mohamed Boudiaf USTO-MB, Oran, Algeria
2 shared publications Latifa Benbihi
2 shared publications- M. Gourine
Service de médecine interne, CHU Oran, faculté de médecine d'Oran, 76, boulevard du Dr-Benzerdjeb, 31000 Oran, Algérie
2 shared publications
Latest Publications
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200572
Status Epilepticus Management in Resource-Limited Settings
Status epilepticus (SE) is a neurologic emergency with disproportionate mortality and morbidity in low- and middle-income countries. Existing SE guidelines are largely based on high-income country contexts, limiting applicability in settings with diagnostic, therapeutic, and infrastructural constraints. We aimed to examine expert clinician perspectives on SE management across recourse-limited settings to identify common barriers and context-specific strategies. This study used a convergent parallel mixed methods approach, interconnecting quantitative and qualitative data collected from an online survey. Experts in SE management were purposively sampled to balance clinical expertise across 3 physician disciplines (neurology, emergency medicine, and critical care) and geographic locations. Invitations to participate were sent to 48 experts from 22 different countries. Qualitative data using thematic analysis and descriptive statistics for quantitative analysis was used. We received responses from 28 clinical experts, spanning 15 countries across 4 continents. Over 96% (27/28) agreed on the importance of guidelines or relevant subsections applicable to resource-limited settings. Experts highlighted inadequate SE education at multiple levels, but less than half (12/28) reported discussing SE management during routine clinic visits. A common theme was a lack of access to anti-seizure medications (ASMs), with 86% (24/28) agreeing that oral ASMs should be included in SE guidelines, although there was no consensus on what these should be. Only 39% (11/28) of experts had consistent access to electroencephalography (EEG), and there was little agreement about the duration and frequency of serial intermittent EEGs in the absence of continuous EEG. Nearly all experts (27/28) agreed that multicenter international efforts are essential to understand current practices and to improve patient outcomes. Other proposed solutions included implementing locally adapted practices to improve care, such as remote tele-monitoring and improving SE education and training. This study provides the most geographically diverse expert insight to date on SE care in recourse-limited settings, underscoring systemic barriers that transcend clinical decision-making. Inclusive, context-sensitive frameworks and implementation strategies are urgently needed. Our findings provide expert-informed priorities to guide future policy, research, and clinical practice for equitable SE care.
- 1 February 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (1) , e200572
Status Epilepticus Management in Resource-Limited Settings
Status epilepticus (SE) is a neurologic emergency with disproportionate mortality and morbidity in low- and middle-income countries. Existing SE guidelines are largely based on high-income country contexts, limiting applicability in settings with diagnostic, therapeutic, and infrastructural constraints. We aimed to examine expert clinician perspectives on SE management across recourse-limited settings to identify common barriers and context-specific strategies. This study used a convergent parallel mixed methods approach, interconnecting quantitative and qualitative data collected from an online survey. Experts in SE management were purposively sampled to balance clinical expertise across 3 physician disciplines (neurology, emergency medicine, and critical care) and geographic locations. Invitations to participate were sent to 48 experts from 22 different countries. Qualitative data using thematic analysis and descriptive statistics for quantitative analysis was used. We received responses from 28 clinical experts, spanning 15 countries across 4 continents. Over 96% (27/28) agreed on the importance of guidelines or relevant subsections applicable to resource-limited settings. Experts highlighted inadequate SE education at multiple levels, but less than half (12/28) reported discussing SE management during routine clinic visits. A common theme was a lack of access to anti-seizure medications (ASMs), with 86% (24/28) agreeing that oral ASMs should be included in SE guidelines, although there was no consensus on what these should be. Only 39% (11/28) of experts had consistent access to electroencephalography (EEG), and there was little agreement about the duration and frequency of serial intermittent EEGs in the absence of continuous EEG. Nearly all experts (27/28) agreed that multicenter international efforts are essential to understand current practices and to improve patient outcomes. Other proposed solutions included implementing locally adapted practices to improve care, such as remote tele-monitoring and improving SE education and training. This study provides the most geographically diverse expert insight to date on SE care in recourse-limited settings, underscoring systemic barriers that transcend clinical decision-making. Inclusive, context-sensitive frameworks and implementation strategies are urgently needed. Our findings provide expert-informed priorities to guide future policy, research, and clinical practice for equitable SE care.
- Open Access
- 10 October 2025
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (8) , 762-767
Impact of fasting during Ramadan on migraine in the Algerian population
- 10 October 2025
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (8) , 762-767
Open AccessImpact of fasting during Ramadan on migraine in the Algerian population
- 15 February 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-10
ABCB1 c.3435 C > T (rs1045642) as a biomarker for carbamazepine efficacy and toxicity in Algerian patients with epilepsy: initial findings report
Epilepsy is among the most prevalent serious neurological disorders, affecting over 70 million people worldwide, in Algeria, the prevalence of epilepsy was estimated to be eight times more common. Carbamazepine is frequently the first-line treatment, making early prediction of patient response essential for personalized care. This approach helps reduce adverse effects and healthcare costs, while enhancing patient outcomes. This study aims to explore the link between the ABCB1 c.3435C > T genetic variation and Carbamazepine resistance and toxicity in Algerian patients with epilepsy, with a focus on the impact of genetic variations on Carbamazepine plasma concentrations and treatment outcomes. Ninety-eight Algerian patients with epilepsy were recruited and categorized as either drug-responsive or drug-resistant based on their clinical response to CBZ treatment. Genotyping of the ABCB1 c.3435 C > T polymorphism was performed using Polymerase Chain Reaction—Restriction Fragment Length Polymorphism (PCR–RFLP) method, and CBZ plasma levels were measured to assess its effect on metabolism. Clinical data, including drug response, therapy type, and adverse drug reactions (ADRs), were collected and analyzed. For the statistical analysis we used chi-squared tests and Exact Fisher's for corrections. Our findings show no significant association between the ABCB1 c.3435C > T genotypes with carbamazepine resistance (p = 0,1) nor incidence of adverse reactions. This polymorphism also indicated no statistically significant link with Carbamazepine plasma levels. The sample size in this study might be limitation; therefore, expanded investigations on Algerian population are needed. Although this study indicates no significant correlation of the ABCB1 c.3435C > T polymorphism with influencing CBZ Pharmacoresistance and therapeutic outcomes, larger-scale-studies are required to confirm these results and assess their reliability.
- 15 February 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-10
ABCB1 c.3435 C > T (rs1045642) as a biomarker for carbamazepine efficacy and toxicity in Algerian patients with epilepsy: initial findings report
Epilepsy is among the most prevalent serious neurological disorders, affecting over 70 million people worldwide, in Algeria, the prevalence of epilepsy was estimated to be eight times more common. Carbamazepine is frequently the first-line treatment, making early prediction of patient response essential for personalized care. This approach helps reduce adverse effects and healthcare costs, while enhancing patient outcomes. This study aims to explore the link between the ABCB1 c.3435C > T genetic variation and Carbamazepine resistance and toxicity in Algerian patients with epilepsy, with a focus on the impact of genetic variations on Carbamazepine plasma concentrations and treatment outcomes. Ninety-eight Algerian patients with epilepsy were recruited and categorized as either drug-responsive or drug-resistant based on their clinical response to CBZ treatment. Genotyping of the ABCB1 c.3435 C > T polymorphism was performed using Polymerase Chain Reaction—Restriction Fragment Length Polymorphism (PCR–RFLP) method, and CBZ plasma levels were measured to assess its effect on metabolism. Clinical data, including drug response, therapy type, and adverse drug reactions (ADRs), were collected and analyzed. For the statistical analysis we used chi-squared tests and Exact Fisher's for corrections. Our findings show no significant association between the ABCB1 c.3435C > T genotypes with carbamazepine resistance (p = 0,1) nor incidence of adverse reactions. This polymorphism also indicated no statistically significant link with Carbamazepine plasma levels. The sample size in this study might be limitation; therefore, expanded investigations on Algerian population are needed. Although this study indicates no significant correlation of the ABCB1 c.3435C > T polymorphism with influencing CBZ Pharmacoresistance and therapeutic outcomes, larger-scale-studies are required to confirm these results and assess their reliability.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 23 (12) , 1463-1473
Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms
Background and Objective: The association between carbamazepine (CBZ) metabolism and resistance in epilepsy and the genetic polymorphisms of CYP3A5 (rs776746 and rs15524) and CYP3A4 (rs2242480, rs2740574, rs35599367, rs12721627, and rs28371759) has been the subject of previous investigations with controversial results. Hence, we conducted a systematic review to assess the potential link between these polymorphisms and CBZ metabolism and resistance Methods: Identifying relevant studies was carried out by searching PubMed, Scopus, PharmGKB, EPIGAD, and PHARMAADME databases up until June 2023. The studies included in our analysis investigated the connection between CYP3A5 (rs776746 and rs15524) and CYP3A4 (rs2242480, rs2740574, rs35599367, rs12721627, and rs28371759) polymorphisms and CBZ metabolism and resistance. Results: This review included a total of 23 studies and more than 2177 epilepsy patients. It was found that the CYP3A4 (rs12721627 and rs28371759) polymorphisms are associated with reduced catalytic activity, whereas the CYP3A4 (rs2740574) polymorphism is linked to lower levels of CBZ-diol and decreased activity. It was also observed that the CYP3A5 (rs776746) polymorphism influences the dose-adjusted plasma levels of CBZ. Conclusion: Although these findings highlight the impact of genetic variations in the CYP3A4 and CYP3A5 genes on CBZ pharmacokinetics and pharmacodynamics, further studies across diverse populations are essential to enhance personalized epilepsy therapy in clinical settings.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 23 (12) , 1463-1473
Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms
Background and Objective: The association between carbamazepine (CBZ) metabolism and resistance in epilepsy and the genetic polymorphisms of CYP3A5 (rs776746 and rs15524) and CYP3A4 (rs2242480, rs2740574, rs35599367, rs12721627, and rs28371759) has been the subject of previous investigations with controversial results. Hence, we conducted a systematic review to assess the potential link between these polymorphisms and CBZ metabolism and resistance Methods: Identifying relevant studies was carried out by searching PubMed, Scopus, PharmGKB, EPIGAD, and PHARMAADME databases up until June 2023. The studies included in our analysis investigated the connection between CYP3A5 (rs776746 and rs15524) and CYP3A4 (rs2242480, rs2740574, rs35599367, rs12721627, and rs28371759) polymorphisms and CBZ metabolism and resistance. Results: This review included a total of 23 studies and more than 2177 epilepsy patients. It was found that the CYP3A4 (rs12721627 and rs28371759) polymorphisms are associated with reduced catalytic activity, whereas the CYP3A4 (rs2740574) polymorphism is linked to lower levels of CBZ-diol and decreased activity. It was also observed that the CYP3A5 (rs776746) polymorphism influences the dose-adjusted plasma levels of CBZ. Conclusion: Although these findings highlight the impact of genetic variations in the CYP3A4 and CYP3A5 genes on CBZ pharmacokinetics and pharmacodynamics, further studies across diverse populations are essential to enhance personalized epilepsy therapy in clinical settings.
- Open Access
- 8 July 2024
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 60 (1) , 1-7
Clinical profile of epilepsy in western Algeria
Background: Epilepsy is one of the most common neurological diseases that affects people of different ages, ethnicities, and geographical locations. The objective of the present study was to determine the demographic and clinical characteristics of epilepsy in west Algerian population. Patients and methods: We enrolled 226 patients with epilepsy and collected data from medical records. We analyzed socio-demographic data, personal and family history, age at onset, seizure types, neurological and psychological findings, etiologies, syndromic classification and comorbidities. Results: In our cohort, the mean age was 27.26 ± 17.57 years and there was no gender predominance. The mean age of seizure onset was 17.11 ± 16.27 years. Genetic epilepsy was the most observed (45.13%). Focal seizures (69.02%) were more frequent than generalized seizures which were mostly represented by absence and tonic–clonic seizures. We reported 51.45% of patients with comorbidities and 16.65% with a history of traumatic brain injury. Conclusion: This is the first report describing the clinical profile and the socio-demographic features in a cohort of patients with epilepsy in the western Algeria. Our results could help to offer personalized care to our patients based on the clinical particularities of their epileptic disorders.
- 8 July 2024
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 60 (1) , 1-7
Open AccessClinical profile of epilepsy in western Algeria
Background: Epilepsy is one of the most common neurological diseases that affects people of different ages, ethnicities, and geographical locations. The objective of the present study was to determine the demographic and clinical characteristics of epilepsy in west Algerian population. Patients and methods: We enrolled 226 patients with epilepsy and collected data from medical records. We analyzed socio-demographic data, personal and family history, age at onset, seizure types, neurological and psychological findings, etiologies, syndromic classification and comorbidities. Results: In our cohort, the mean age was 27.26 ± 17.57 years and there was no gender predominance. The mean age of seizure onset was 17.11 ± 16.27 years. Genetic epilepsy was the most observed (45.13%). Focal seizures (69.02%) were more frequent than generalized seizures which were mostly represented by absence and tonic–clonic seizures. We reported 51.45% of patients with comorbidities and 16.65% with a history of traumatic brain injury. Conclusion: This is the first report describing the clinical profile and the socio-demographic features in a cohort of patients with epilepsy in the western Algeria. Our results could help to offer personalized care to our patients based on the clinical particularities of their epileptic disorders.
- 18 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105299
Safety and Efficacy of Disease Modifying Therapies After Switching from Natalizumab: A MENACTRIMS Observational Study
- 18 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105299
Safety and Efficacy of Disease Modifying Therapies After Switching from Natalizumab: A MENACTRIMS Observational Study
- 24 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (4) , 871-880
The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review
Despite a dramatic increase in treatment options over the past 30 years, Carbamazepine (CBZ) is still considered the standard of care and the most prescribed initial treatment for focal epilepsy. Hence, the identification of genetic biomarkers that influence the response, resistance and toxicity to CBZ remains a challenge. Several research studies have looked into this to highlight the polymorphisms responsible for the variability in the response to CBZ in patients with epilepsy. The aim of this review is to compare the different results published in the literature The systematic review included thirty-nine studies (2005–2021), Meta-analyses were performed on more than twelve polymorphisms in three genes (ABCB1, ABCC2, RALBP1) involved in CBZ cell transport. The current challenges are to identify other new biomarkers of antiepileptic drugs that can only materialize with large-scale collaborative research efforts.
- 24 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (4) , 871-880
The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review
Despite a dramatic increase in treatment options over the past 30 years, Carbamazepine (CBZ) is still considered the standard of care and the most prescribed initial treatment for focal epilepsy. Hence, the identification of genetic biomarkers that influence the response, resistance and toxicity to CBZ remains a challenge. Several research studies have looked into this to highlight the polymorphisms responsible for the variability in the response to CBZ in patients with epilepsy. The aim of this review is to compare the different results published in the literature The systematic review included thirty-nine studies (2005–2021), Meta-analyses were performed on more than twelve polymorphisms in three genes (ABCB1, ABCC2, RALBP1) involved in CBZ cell transport. The current challenges are to identify other new biomarkers of antiepileptic drugs that can only materialize with large-scale collaborative research efforts.
- 1 January 2022
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
- Vol. 6 (13)
Ketogenic diet: a therapeutic alternative in pediatric refractory epilepsies
Several studies have demonstrated the effectiveness of ketogenic diet (KD) on refractory epilepsies, especially in children. In this category of patients, a strong collaboration between the healthcare providers and the full engagement of parents is required. The regimen is significantly effective for different types of epilepsy that are resistant to medical treatment. It can also be used as a first-line treatment, given its well tolerance. Treatment has been rolled out for children but research into its use in adults is promising. There is no international or national protocol, the implementation of this diet follows a rigor being specific to every ketogenic center. The understanding of the underlying mechanisms is not well elucidated, it would make it possible to optimize the clinical use of the ketogenic diet, but also to develop novel antiepileptic treatments. This article aims to review the different variants of KD and their prescription terms in children with intractable epilepsy. Keywords: drug-resistant epilepsy, ketogenic diet, children, Modified Atkins Diet.
- 1 January 2022
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
- Vol. 6 (13)
Ketogenic diet: a therapeutic alternative in pediatric refractory epilepsies
Several studies have demonstrated the effectiveness of ketogenic diet (KD) on refractory epilepsies, especially in children. In this category of patients, a strong collaboration between the healthcare providers and the full engagement of parents is required. The regimen is significantly effective for different types of epilepsy that are resistant to medical treatment. It can also be used as a first-line treatment, given its well tolerance. Treatment has been rolled out for children but research into its use in adults is promising. There is no international or national protocol, the implementation of this diet follows a rigor being specific to every ketogenic center. The understanding of the underlying mechanisms is not well elucidated, it would make it possible to optimize the clinical use of the ketogenic diet, but also to develop novel antiepileptic treatments. This article aims to review the different variants of KD and their prescription terms in children with intractable epilepsy. Keywords: drug-resistant epilepsy, ketogenic diet, children, Modified Atkins Diet.
- Open Access
- 31 December 2021
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 27 (1(supple)) , 56-57
Guillain Barré Syndrome: A Rare Neurological Manifestation of COVID-19
- 31 December 2021
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 27 (1(supple)) , 56-57
Open AccessGuillain Barré Syndrome: A Rare Neurological Manifestation of COVID-19
- 1 September 2021
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 12 (3) , 212-218
L’artérite à cellules géantes : atteintes neurologiques et contribution des nouvelles modalités d’imagerie au diagnostic
- 1 September 2021
- Published by Elsevier in Pratique Neurologique - FMC
- Vol. 12 (3) , 212-218
L’artérite à cellules géantes : atteintes neurologiques et contribution des nouvelles modalités d’imagerie au diagnostic